{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T02:56:10Z","timestamp":1772679370075,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T00:00:00Z","timestamp":1242172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s10549-009-0417-y","type":"journal-article","created":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T09:02:11Z","timestamp":1242118931000},"page":"701-705","source":"Crossref","is-referenced-by-count":38,"title":["Association of interleukin-10 gene variation with breast cancer prognosis"],"prefix":"10.1007","volume":"119","author":[{"given":"Armin","family":"Gerger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Renner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Langsenlehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Knechtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Szkandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellmut","family":"Samonigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krippl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Langsenlehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,13]]},"reference":[{"issue":"3","key":"417_CR1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00129785-200101030-00005","volume":"1","author":"B Rannala","year":"2001","unstructured":"Rannala B (2001) Finding genes influencing susceptibility to complex diseases in the post-genome era. Am J Pharmacogenomics 1(3):203\u2013221. doi: 10.2165\/00129785-200101030-00005","journal-title":"Am J Pharmacogenomics"},{"key":"417_CR2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, Peterse JL, van\u2018t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591\u2013602. doi: 10.1038\/nrc1670","journal-title":"Nat Rev Cancer"},{"key":"417_CR3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2002","unstructured":"Parkin DM, Bray F, Ferlay J et al (2002) Global cancer statistics. CA Cancer J Clin 55:74\u2013108. doi: 10.3322\/canjclin.55.2.74","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"417_CR4","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.4161\/cc.4.12.2258","volume":"4","author":"K Hunter","year":"2005","unstructured":"Hunter K (2005) The intersection of inheritance and metastasis: the role and implications of germline polymorphism in tumor dissemination. Cell Cycle 4(12):1719\u20131721","journal-title":"Cell Cycle"},{"key":"417_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/BD-2007-26114","volume":"26","author":"SM Hsieh","year":"2007","unstructured":"Hsieh SM, Lintell NA, Hunter KW (2007) Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer. Breast Dis 26:157\u2013162","journal-title":"Breast Dis"},{"issue":"2","key":"417_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrc1803","volume":"6","author":"K Hunter","year":"2006","unstructured":"Hunter K (2006) Breast host genetics influence tumour metastasis. Nat Rev Cancer 6(2):141\u2013146. doi: 10.1038\/nrc1803","journal-title":"Nat Rev Cancer"},{"issue":"28","key":"417_CR7","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","volume":"26","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672\u20134678. doi: 10.1200\/JCO.2008.16.1612","journal-title":"J Clin Oncol"},{"issue":"13","key":"417_CR8","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2004.04.900","volume":"22","author":"HJ Lenz","year":"2004","unstructured":"Lenz HJ (2004) The use and development of germline polymorphisms in clinical oncology. J Clin Oncol 22(13):2519\u20132521. doi: 10.1200\/JCO.2004.04.900","journal-title":"J Clin Oncol"},{"key":"417_CR9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-006-9253-5","volume":"100","author":"DF Hayes","year":"2006","unstructured":"Hayes DF, Ethier S, Mippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100:237\u2013238. doi: 10.1007\/s10549-006-9253-5","journal-title":"Breast Cancer Res Treat"},{"key":"417_CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"LM McShane","year":"2006","unstructured":"McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229\u2013235. doi: 10.1007\/s10549-006-9242-8","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"417_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1025752420309","volume":"81","author":"U Langsenlehner","year":"2003","unstructured":"Langsenlehner U, Krippl P, Renner W et al (2003) The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res Treat 81(2):169\u2013172. doi: 10.1023\/A:1025752420309","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"417_CR12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-004-3607-7","volume":"90","author":"U Langsenlehner","year":"2005","unstructured":"Langsenlehner U, Krippl P, Renner W et al (2005) Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 90(2):113\u2013115. doi: 10.1007\/s10549-004-3607-7","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"417_CR13","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djh289","volume":"96","author":"P Krippl","year":"2004","unstructured":"Krippl P, Langsenlehner U, Renner W et al (2004) Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96(19):1478\u20131479","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"417_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0304-3835(03)00468-3","volume":"201","author":"P Krippl","year":"2003","unstructured":"Krippl P, Langsenlehner U, Renner W et al (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201(2):181\u2013184. doi: 10.1016\/S0304-3835(03)00468-3","journal-title":"Cancer Lett"},{"issue":"1","key":"417_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/B:BREA.0000041574.90735.ea","volume":"87","author":"U Langsenlehner","year":"2004","unstructured":"Langsenlehner U, Krippl P, Renner W et al (2004) Genetic variants of the sulfotransferase 1A1 and breast cancer risk. Breast Cancer Res Treat 87(1):19\u201322. doi: 10.1023\/B:BREA.0000041574.90735.ea","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"417_CR16","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1158\/1078-0432.CCR-05-2055","volume":"12","author":"U Langsenlehner","year":"2006","unstructured":"Langsenlehner U, Yazdani-Biuki B, Eder T et al (2006) The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 12(4):1392\u20131394. doi: 10.1158\/1078-0432.CCR-05-2055","journal-title":"Clin Cancer Res"},{"issue":"2","key":"417_CR17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-006-9408-4","volume":"104","author":"A Gerger","year":"2007","unstructured":"Gerger A, Langsenlehner U, Renner W et al (2007) A multigenetic approach to predict breast cancer risk. Breast Cancer Res Treat 104(2):159\u2013164. doi: 10.1007\/s10549-006-9408-4","journal-title":"Breast Cancer Res Treat"},{"key":"417_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2003.11.001","volume":"15","author":"S Mocellin","year":"2004","unstructured":"Mocellin S, Marincola F, Rossi CR et al (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61\u201376. doi: 10.1016\/j.cytogfr.2003.11.001","journal-title":"Cytokine Growth Factor Rev"},{"key":"417_CR19","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.147.11.3815","volume":"147","author":"DF Fiorentino","year":"1991","unstructured":"Fiorentino DF, Zlotnik A, Mosmann TR et al (1991) IL10 inhibits cytokine production by activated macrophages. J Immunol 147:3815\u20133822","journal-title":"J Immunol"},{"key":"417_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2370.1997.tb00001.x","volume":"24","author":"DM Turner","year":"1997","unstructured":"Turner DM, Williams DM, Sankaran D et al (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1\u20138","journal-title":"Eur J Immunogenet"},{"key":"417_CR21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y","volume":"42","author":"E Crawley","year":"1999","unstructured":"Crawley E, Kay R, Sillibourne J et al (1999) Polymorphic haplotypes of the interleukin-10 5\u2019 flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42:1101\u20131108. doi: 10.1002\/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y","journal-title":"Arthritis Rheum"},{"key":"417_CR22","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa022060","volume":"349","author":"MT Lin","year":"2003","unstructured":"Lin MT, Storer B, Martin PJ et al (2003) Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349:2201\u20132210. doi: 10.1056\/NEJMoa022060","journal-title":"N Engl J Med"},{"key":"417_CR23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bmt.1702126","volume":"25","author":"E Holler","year":"2000","unstructured":"Holler E, Roncarolo MG, Hintermeier-Knabe R et al (2000) Prognostic significance of increased IL10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 25:237\u2013241. doi: 10.1038\/sj.bmt.1702126","journal-title":"Bone Marrow Transplant"},{"key":"417_CR24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2407-6-188","volume":"6","author":"SP Balasubramanian","year":"2006","unstructured":"Balasubramanian SP, Azmy IA, Higham SE et al (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188. doi: 10.1186\/1471-2407-6-188","journal-title":"BMC Cancer"},{"issue":"2","key":"417_CR25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10689-005-0072-3","volume":"5","author":"WM Howell","year":"2006","unstructured":"Howell WM, Rose-Zerilli MJ (2006) Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 5(2):143\u2013149. doi: 10.1007\/s10689-005-0072-3","journal-title":"Fam Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-009-0417-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0417-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T02:59:43Z","timestamp":1684983583000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-009-0417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,13]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1007\/s10549-009-0417-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,13]]}}}